Literatura académica sobre el tema "Ligase IV Inhibitor SCR7"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Ligase IV Inhibitor SCR7".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Ligase IV Inhibitor SCR7"
Anuchina, Arina A., Milyausha I. Zaynitdinova, Anna G. Demchenko, Nadezhda A. Evtushenko, Alexander V. Lavrov y Svetlana A. Smirnikhina. "Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7". International Journal of Molecular Sciences 24, n.º 7 (4 de abril de 2023): 6704. http://dx.doi.org/10.3390/ijms24076704.
Texto completoGreco, George E., Yoshihiro Matsumoto, Rhys C. Brooks, Zhengfei Lu, Michael R. Lieber y Alan E. Tomkinson. "SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV". DNA Repair 43 (julio de 2016): 18–23. http://dx.doi.org/10.1016/j.dnarep.2016.04.004.
Texto completoCalimeri, Teresa, Daniele Caracciolo, Nicola Amodio, Mehmet Kemal Samur, Marzia Leotta, Mariateresa Fulciniti, Marco Rossi et al. "Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability". Blood 124, n.º 21 (6 de diciembre de 2014): 3417. http://dx.doi.org/10.1182/blood.v124.21.3417.3417.
Texto completoGreco, George E., Zane A. Conrad, Alycia M. Johnston, Qingyao Li y Alan E. Tomkinson. "Synthesis and structure determination of SCR7, a DNA ligase inhibitor". Tetrahedron Letters 57, n.º 29 (julio de 2016): 3204–7. http://dx.doi.org/10.1016/j.tetlet.2016.06.037.
Texto completoKotnis, Ashwin y Rita Mulherkar. "Novel inhibitor of DNA ligase IV with a promising cancer therapeutic potential". Journal of Biosciences 39, n.º 3 (29 de abril de 2014): 339–40. http://dx.doi.org/10.1007/s12038-014-9433-0.
Texto completoSallmyr, Annahita y Feyruz V. Rassool. "Up-Regulated WRN and DNA Ligase IIIα Are Involved in Alternative NHEJ Repair Pathway of DNA Double Strand Breaks (DSB) in Chronic Myeloid Leukemia (CML)." Blood 110, n.º 11 (16 de noviembre de 2007): 1016. http://dx.doi.org/10.1182/blood.v110.11.1016.1016.
Texto completoChou, Mei-Chia, Yuan-Jia Lee, Yao-Ting Wang, Shi-Yie Cheng y Hsueh-Ling Cheng. "Cytotoxic and Anti-Inflammatory Triterpenoids in the Vines and Leaves of Momordica charantia". International Journal of Molecular Sciences 23, n.º 3 (19 de enero de 2022): 1071. http://dx.doi.org/10.3390/ijms23031071.
Texto completoDevassy, Greeshma, Ranjith Ramachandran, Kottarapat Jeena, Vijayabhaskar R. Junnuthula, Vindya K. Gopinatha, Cheripelil Manju, Maneesh Manohar, Shantikumar V. Nair, Sathees C. Raghavan y Manzoor Koyakutty. "Simultaneous release of two drugs from polymer nano-implant inhibits recurrence in glioblastoma spheroids". Precision Nanomedicine 2, n.º 1 (1 de febrero de 2019): 218–29. http://dx.doi.org/10.33218/prnano2(1).181122.1.
Texto completoCha, Sang-Wook. "Generating Nonmosaic Mutants in Xenopus Using CRISPR–Cas in Oocytes". Cold Spring Harbor Protocols 2022, n.º 6 (8 de julio de 2021): pdb.prot106989. http://dx.doi.org/10.1101/pdb.prot106989.
Texto completoShima, Yutaka, Takito Shima, Tomoki Chiba, Tatsuro Irimura y Issay Kitabayashi. "PML Protects HIPK2 and p300 from SCF-Mediated Ubiquitin-Dependent Degradation To Activate Transcription." Blood 110, n.º 11 (16 de noviembre de 2007): 2653. http://dx.doi.org/10.1182/blood.v110.11.2653.2653.
Texto completoTesis sobre el tema "Ligase IV Inhibitor SCR7"
Menchon, Grégory. "Criblage virtuel et fonctionnel sur le complexe XRCC4/ADN ligase IV/Cer-XLF de ligature des cassures double-brin de l'ADN : application en radiosensibilisation tumorale". Thesis, Toulouse 3, 2015. http://www.theses.fr/2015TOU30395.
Texto completoRadiotherapy is a major weapon used against cancer. Radio-induced DNA double strand breaks (DSB) are the main lesions responsible for cell death. Non-homologous end-joining (NHEJ) is a predominant DSB repair mechanism which contributes to cancer cells resistance to radiotherapy. NHEJ is thus a good target for strategies which aim at increasing the radio-sensitivity of tumors. Through in silico screening and biophysical and biochemical assays, our objective was to find specific ligands for the XRCC4/Lig4 and XRCC4/Cer-XLF protein-protein interactions involved in NHEJ. Here, we isolated the first compounds able to prevent their interaction in vitro. These early stage inhibitors are promising tools for cancer therapy with the hope to develop more specific compounds for cellular assays through the 3D structure of the protein/inhibitor complexes
Pandey, Monica. "Understanding the Sequence Dependence of NHEJ Mediated Double-strand Break Repair, and Identification of Novel DNA Ligase Inhibitors and their Potential Use as Cancer Therapeutics". Thesis, 2017. http://etd.iisc.ac.in/handle/2005/4146.
Texto completoActas de conferencias sobre el tema "Ligase IV Inhibitor SCR7"
Lin, Tingting, Zhilian Zhou, Lifeng Zhu, Yandan Fan, Xiaofen Ding y Yingming Sun. "Abstract 3066: DNA ligase IV inhibitor and X-ray exert a synthetic lethal in loss-of-function p53 cells". En Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-3066.
Texto completo